(secondQuint)A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment.

 This study will look at the effect of a single does of study medication in three groups.

 Each group will have 6 - 8 subjects with similar levels of hepatic impairment.

 Group 1 will have normal hepatic function.

 Groups 2 and 3 will be made up of subjects with mild to moderate hepatic impairment.

 Subjects will have blood taken at specific intervals to measure study medication levels.

 Subject participation will last approximately 7 to 9 days.

.

 A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment@highlight

This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment.

 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.

